Annovis Bio to Present Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania

Annovis Bio

BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce its CEO Maria Maccecchini, Ph.D. will present the Company’s novel approach to treating PD at the University of Pennsylvania Perelman School of Medicine’s Parkinson’s Disease and Movement Disorders Center (PD&MDC).

The talk, “Rethinking Parkinson’s Disease”, takes place Monday, July 20, 2020, at 1:00 p.m. ET.

Recognized by the Parkinson’s Foundation as one of 45 worldwide Centers of Excellence, the PD&MDC is one of the largest of its kind in the country and the preeminent in the Philadelphia region, providing care to thousands of patients each year.

Dr. Maccecchini will discuss how high levels of neurotoxic proteins begin a toxic cascade, leading to impaired axonal transport, inflammation, nerve cell death and loss of cognitive and motor functions in PD, AD and other neurodegenerative diseases.

READ:  Vishay Intertechnology NTC Thermistor With Long PEEK-Insulated, NiFe Leads Delivers Fast, High Accuracy Measurement

Dr. Maccecchini will present data demonstrating reversal of the toxic cascade in animals and humans using ANVS401, Annovis Bio’s lead compound, as well as discuss the Company’s latest Phase 2 clinical trial targeting early AD and PD, including trial sites and clinical timelines.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee